Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 24

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 24
---
. Our Compensation Committee reviews and recommends policies relating to compensation and benefits of our officers and employees. The Compensation Committee held seven (7) meetings during the last fiscal year. The Compensation Committee operates under a written charter that satisfies the applicable standards of the SEC and The Nasdaq Stock Market and is currently available at ir.supernus.com/corporate-governance. The Compensation Committee’s responsibilities include: • reviewing and approving corporate goals and objectives and performance goals relevant to the compensation of our CEO and other executive officers; • evaluating the performance of our executive officers in light of those goals and objectives; • setting the compensation of our executive officers, other than the CEO, based on such evaluations and the assessment of our compensation program in conjunction with our compensation consultant; • reviewing and recommending for approval by the independent directors on the Board of Directors, the compensation of our CEO based on the Compensation Committee’s review of the CEO’s performance; • making recommendations to the Board of Directors regarding the adoption of incentive compensation plans and equity-based plans, as well as the Company’s 401(k) plan, and administering the Company’s existing incentive compensation plans and equity-based plans; • making recommendations to the Board of Directors regarding the compensation of directors; • reviewing and discussing with management the Compensation Discussion and Analysis to be included in the Company’s filings with the SEC, and recommending to the Board of Directors 14 whether such Compensation Discussion and Analysis should be included in the Company’s annual proxy statement or annual report; • preparing a written report to be included in the Company’s annual proxy statement for each Annual Meeting of Stockholders; • overseeing management’s succession planning for succession of senior management positions including the position of CEO; • annually reviewing and evaluating the performance of the Compensation Committee and its members, including compliance of the Compensation Committee with its charter; • periodically reviewing the Compensation Committee charter; and • engaging and collaborating with an independent compensation consultant to establish a peer group and assess the Company’s compensation policies and practices in relation to such peer group. Governance and Nominating Committee The current members of our Governance and Nominating Committee are Mr. Newhall, who is the chair of the committee and Drs. Barlow and Gemayel. Each of the members of our Governance and Nominating Committee are independent under the applicable rules and regulations of the SEC and The Nasdaq Stock Market. The Governance and Nominating Committee did not hold a meeting during the last fiscal year. The Governance and Nominating Committee operates under a written charter that satisfies the applicable standards of the SEC and